Terminated PHASE3 INTERVENTIONAL 2-arm NCT00005834

S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma

A Phase III Trial of Dexamethasone, Cyclophosphamide, Etoposide, Cisplatin (DCEP) and G-CSF With or Without Thalidomide (NSC #66847) as Salvage Therapy for Patients With Refractory Multiple Myeloma

Sponsor: National Cancer Institute (NCI)

Conditions Multiple Myeloma

Interventions cisplatin cyclophosphamide dexamethasone etoposide filgrastim thalidomide

Updated 8 times since 2017 Last updated: Mar 5, 2015 Started: Apr 30, 2000 Primary completion: Nov 30, 2003 Completion: Nov 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

poor accrual

Other terminated trials from National Cancer Institute (NCI)

See all terminations from National Cancer Institute (NCI)

Other Multiple Myeloma trials with similar outcome

Browse all Multiple Myeloma trials

Listed as NCT00005834, this PHASE3 trial focuses on Multiple Myeloma and remains terminated or withdrawn. Sponsored by National Cancer Institute (NCI), it has been updated 8 times since 2000, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
May 2023 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — May 2023 [monthly]

Terminated PHASE3

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Apr 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
SWOG Cancer Research Network

Data source: SWOG Cancer Research Network

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albuquerque, United States , Ann Arbor, United States , Atlanta, United States , Atlantis, United States , Billings, United States , Biloxi, United States , Boston, United States , Chicago, United States , Cincinnati, United States , Cleveland, United States and 52 more locations